March 08, 2026 a 12:38 pm
BMY: Analysts Ratings - Bristol-Myers Squibb Company
Bristol-Myers Squibb Company, a leader in the biopharmaceutical field, has recently shown a steady increase in Hold ratings, indicating a period of cautious investor sentiment. With a focus on a diverse product line addressing hematology, oncology, cardiovascular, immunology, and other therapeutic areas, the company's stock continues to be a point of focus for analysts. Investors are watching for growth accelerators within their portfolio, especially in oncology and cardiovascular drugs.
Historical Stock Grades
| Recommendation | Number | Score |
|---|---|---|
| Strong Buy | 4 | |
| Buy | 6 | |
| Hold | 18 | |
| Sell | 1 | |
| Strong Sell | 0 |
Sentiment Development
Over recent months, there has been a notable increase in 'Hold' ratings, likely indicating a cautious stance from analysts as the company navigates its market position and future opportunities. The 'Buy' and 'Strong Buy' categories have remained relatively stable, though slightly less emphasized than previous periods. The overall sentiment reflects careful anticipation as investors await further financial metrics and innovation from the company's pipeline.
- The total number of 'Hold' ratings increased from 17 to 18 over the past three months.
- 'Buy' ratings have seen a minor adjustment, currently standing at 6.
- Significant decrease observed in 'Strong Buy' ratings from earlier in 2025.
Percentage Trends
The shift from 'Strong Buy' to 'Hold' ratings suggests a more cautious approach by analysts. This shift is primarily observed over the last year, with the percentage of 'Strong Buy' ratings decreasing while 'Hold' ratings increase. Such realignment might suggest market uncertainties or changes in strategic focus within the company's business model. This trend highlights the importance of monitoring upcoming earnings reports and market responses to the company's newly introduced products.
- 'Hold' ratings have increased to 72% as of March 2026.
- 'Strong Buy' represents now only 16% of the ratings.
- 'Buy' ratings hold a moderate position, showing 24% of the pie.
Latest Analyst Recommendations
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-02-23 | Overweight | Overweight | Piper Sandler |
| 2026-02-06 | Neutral | Neutral | Citigroup |
| 2026-02-06 | Buy | Buy | Guggenheim |
| 2026-02-06 | Equal Weight | Equal Weight | Wells Fargo |
| 2026-01-28 | Overweight | Overweight | Piper Sandler |
Analyst Recommendations with Change of Opinion
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-01-07 | Buy | Neutral | UBS |
| 2025-12-15 | Buy | Neutral | B of A Securities |
| 2025-12-12 | Buy | Neutral | Guggenheim |
| 2025-04-08 | Neutral | Buy | Goldman Sachs |
| 2024-12-16 | Buy | Hold | Jefferies |
Interpretation
The overall assessment indicates a conservative perspective on Bristol-Myers Squibb's near-term opportunities and market behavior. Analysts seem to be hedging their positions amidst fluctuating evaluation metrics and external economic conditions. Although there are analyses signaling optimistic trends with consistent 'Buy' upgrades, widespread 'Hold' ratings suggest concern about unforeseen market changes. Analyst sentiments currently suggest a moderate but composed level of confidence in the company's ability to navigate potential challenges.
Conclusion
Bristol-Myers Squibb Company is under close scrutiny by analysts, reflecting a balance of potential growth aligned with market hesitations. The significant trend towards 'Hold' ratings underscores a wait-and-see approach as investors anticipate upcoming product performances and strategic decisions. While 'Strong Buy' sentiments have softened, spurts of upgrades indicate underlying confidence in Bristol-Myers Squibb's competitive stance. Continuous assessment of newly released drugs and their market impact will be crucial for evaluating future conviction levels.